| Oral anticoagulation |
51 (54.8) |
| Calcium channel blockers |
9 (9.7%) |
| PDE-5 I |
24 (25.8%) |
| ERA |
30 (32.3%) |
| Prostanoids |
9 (9.7%) |
| Combination therapy |
6 (6.6 %) |
|
| ERA= Endothelin receptor antagonist, PDE-5 I= Phosphodiesterase type-5 inhibitor |
| Table 3: Therapeutic options at time of diagnosis |
